Key Highlights

  • The FDA grants Fast Track Designation to Telix Pharmaceuticals' BiPASS prostate imaging program.
  • BiPASS evaluates gallium-68 PSMA-PET imaging combined with MRI before prostate biopsy.
  • Telix has completed enrolment in the Phase 3 BiPASS study but has not reported results.
  • The company plans an NDA submission, although no submission or decision date has been provided.

Telix Pharmaceuticals Limited (ASX:TLX) has received US Food and Drug Administration Fast Track designation for BiPASS, its pre-biopsy prostate imaging program. The program combines gallium-68 PSMA-PET imaging with MRI before biopsy, while the designation creates a pathway for more frequent engagement with the regulator as Telix works toward a planned new drug application.

Fast Track Opens a Regulatory Channel

Fast Track is designed to facilitate development and potentially expedite review for therapies or products addressing serious conditions and unmet medical needs. For BiPASS, the designation may support closer FDA interaction, but it is not an approval. Use of Illuccix and Gozellix in the pre-biopsy setting remains investigational and has not been approved by the FDA or another regulatory authority.

BiPASS Targets the Pre-Biopsy Pathway

The program uses PSMA-PET and MRI before biopsy. Earlier PRIMARY and PRIMARY2 studies cited in the document found that the combined imaging approach could improve detection of clinically significant prostate cancer while reducing unnecessary biopsies by almost 50%. Those earlier findings do not represent results from the Phase 3 BiPASS population.

Phase 3 Data Remain the Key Evidence

Telix has completed enrolment in its Phase 3 BiPASS study, which examines Illuccix and Gozellix for pre-biopsy diagnosis. No Phase 3 results were reported in the supplied material. The eventual regulatory outcome will therefore depend on the study data and the FDA's assessment of the planned application.

NDA Timing Is Still Open

Telix says it is engaged with the FDA on an NDA pathway for the BiPASS indication. However, the document provides no submission date, expected decision date or estimate of a commercial opportunity. Fast Track status can support the process but does not guarantee acceptance, accelerated review or approval.

What Comes Next

The next steps centre on Phase 3 evidence, continued FDA engagement and a planned NDA submission, with the company yet to provide a timetable for filing or review.